Lewis Thomas J, Mitchell Doug
Department of Oncology, Liu Hua Qiao Hospital, Guangzhou, PR China.
Integr Cancer Ther. 2008 Jun;7(2):96-102. doi: 10.1177/1534735408319065.
There are increasing data showing that sonodynamic therapy (SDT), which refers to a synergistic effect of drugs and ultrasound, is a promising new modality for cancer treatment. However, few clinical data on SDT have been published. One reason is the lack of suitable drugs for clinical SDT use. Recently a new sonosensitizing agent has been developed by SonneMed, LLC, referred to as SF1. In this study the effect of SDT with SF1 on S-180 sarcoma in mice was examined. The tumor bearing mice were allocated to the following groups: (1) sham-treatment (control, C); (2) ultrasound treatment (only ultrasound treatment, 1.2 mW/cm2 , without SF1, U); (3) SF1 treatment (SF1 20 mg/kg intraperitoneal [ip] without ultrasound treatment, S); and (4) SF1 + ultrasound treatment (SU). Following treatment, tumor volume was monitored. Tumor growth inhibition was seen only in group SU, and with increasing ultrasound intensity, the inhibitory effect was enhanced. Tumor growth inhibition was also visible even when covered by a barrier of bone. Pathological slices showed coagulated necrosis or metamorphic tissue with inflammatory reaction in the tumor taken from 2 to 36 hours after SDT. These data revealed that SDT with SF1 did inhibit growth of mouse S-180 sarcoma and the inhibitory effect was sound intensity dependent. SDT also induced some inflammation while it destroyed the tumor, indicative of a "vaccine" effect. SF1 shows great promise for clinical use in the future.
越来越多的数据表明，声动力疗法（SDT），即药物与超声的协同效应，是一种很有前景的癌症治疗新方法。然而，关于声动力疗法的临床数据鲜有发表。原因之一是缺乏适用于临床声动力疗法的药物。最近，SonneMed有限责任公司研发出一种新的声敏剂，称为SF1。在本研究中，检测了SF1声动力疗法对小鼠S-180肉瘤的影响。将荷瘤小鼠分为以下几组：（1）假治疗组（对照组，C）；（2）超声治疗组（仅超声治疗，1.2 mW/cm2，无SF1，U）；（3）SF1治疗组（腹腔注射[ip]20 mg/kg SF1，无超声治疗，S）；以及（4）SF1+超声治疗组（SU）。治疗后，监测肿瘤体积。仅在SU组观察到肿瘤生长抑制，且随着超声强度增加，抑制作用增强。即使被骨屏障覆盖，肿瘤生长抑制也可见。病理切片显示，声动力疗法后2至36小时取自肿瘤的切片出现凝固性坏死或伴有炎症反应的变质组织。这些数据表明，SF1声动力疗法确实抑制了小鼠S-180肉瘤的生长，且抑制作用与声强有关。声动力疗法在破坏肿瘤的同时还引发了一些炎症，显示出“疫苗”效应。SF1在未来临床应用中显示出巨大潜力。
